Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo for advanced breast cancer shows promise but trial halted early

NCT ID NCT05085002

Terminated Disease control Sponsor: EQRx, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tested a new drug called lerociclib combined with standard hormone therapy in 100 people with advanced HR+/HER2- breast cancer. The goal was to see if the combination is safe and effective. However, the trial was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
lerociclib (a targeted drug) combined with letrozole or fulvestrant (hormone therapies), plus goserelin for premenopausal participants
What this could lead to
If it worked, this could point toward a new treatment option for advanced breast cancer that is hormone receptor-positive and HER2-negative.
What could go wrong
The trial was terminated early, so results are limited. It was a small, single-arm phase 2 study, meaning no comparison group, and the drug may not prove effective or safe in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CANCER

Contacts and locations

Locations

  • ARENSIA Exploratory Medicine LLC

    Tbilisi, 0112, Georgia

  • CHA Libramont

    Libramont, 6800, Belgium

  • Cancer Care Associates of York, Inc.

    York, Pennsylvania, 17403, United States

  • Cancer Specialists of North Florida

    Jacksonville, Florida, 32256, United States

  • Clinique Saint-Pierre asbl

    Ottignies, 1340, Belgium

  • IMSP Institutul Oncologic, Arsenia Exploratory Medicine

    Chisinau, MD-2025, Moldova

  • Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"

    Meldola, 47014, Italy

  • LTD "Brothers"

    Batumi, 6010, Georgia

  • LTD "Health House"

    Tbilisi, 0144, Georgia

  • Ltd "Multiprofile Clinic Consilium Medulla "

    Tbilisi, 0186, Georgia

  • Ltd Israeli-Georgian Medical Research Clinic Helsicore

    Tbilisi, 0112, Georgia

  • Nebraska Cancer Specialists

    Omaha, Nebraska, 68130, United States

  • Northwest Medical Specialties PLLC

    Tacoma, Washington, 98405, United States

  • Oregon Oncology Specialists

    Salem, Oregon, 97301, United States

  • PanAmerican Clinical Research Cuernavaca

    Cuernavaca, 66290, Mexico

  • PanAmerican Clinical Research Guadalajara

    Guadalajara, Jalisco, 44670, Mexico

  • PanAmerican Clinical Research, Queretaro

    Querétaro, 76100, Mexico

  • Tranquil Clinical Research

    Webster, Texas, 16969, United States

  • UZA

    Edegem, 2650, Belgium

  • Ziekenhuizen K.U.Leuven, Campus gasthuisberg

    Leuven, 3000, Belgium

  • vzw Verenigde Ziekenhuizen van Waas en Durme - VITAZ

    Sint-Niklaas, 9100, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.